Peritoneal Tumor – Pipeline Review, H2 2013

Summary

Global Markets Direct’s, ‘Peritoneal Tumor – Pipeline Review, H2 2013’, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Tumor. Peritoneal Tumor – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– A snapshot of the global therapeutic scenario for Peritoneal Tumor.

– A review of the Peritoneal Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

– Coverage of products based on various stages of development ranging from discovery till registration stages.

– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

– Coverage of the Peritoneal Tumor pipeline on the basis of route of administration and molecule type.

– Key discontinued pipeline projects.

– Latest news and deals relating to the products.

Reasons to buy

– Identify and understand important and diverse types of therapeutics under development for Peritoneal Tumor.

– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

– Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

– Devise corrective measures for pipeline projects by understanding Peritoneal Tumor pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Peritoneal Tumor Overview 7

Therapeutics Development 8

An Overview of Pipeline Products for Peritoneal Tumor 8

Peritoneal Tumor Therapeutics under Development by Companies 10

Peritoneal Tumor Therapeutics under Investigation by Universities/Institutes 12

Late Stage Products 13

Comparative Analysis 13

Mid Clinical Stage Products 14

Comparative Analysis 14

Early Clinical Stage Products 15

Comparative Analysis 15

Peritoneal Tumor Therapeutics - Products under Development by Companies 16

Peritoneal Tumor Therapeutics - Products under Investigation by Universities/Institutes 17

Companies Involved in Peritoneal Tumor Therapeutics Development 18

Boehringer Ingelheim GmbH 18

Amgen Inc. 19

Eli Lilly and Company 20

Daiichi Sankyo Company, Ltd 21

Cell Therapeutics, Inc. 22

Marshall Edwards, Inc. 23

CritiTech, Inc. 24

RECEPTA Biopharma S.A. 25

Peritoneal Tumor - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

trebananib - Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

paclitaxel poliglumex - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ramucirumab - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

idronoxil - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

nintedanib - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

exatecan mesylate - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

RebmAb-100 - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

paclitaxel - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

EGEN-001 - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ABT-767 - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

²¹²Pb-TCMC-Trastuzumab - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Peritoneal Tumor Therapeutics - Drug Profile Updates 57

Peritoneal Tumor Therapeutics - Discontinued Products 63

Peritoneal Tumor Therapeutics - Dormant Products 64

Peritoneal Tumor - Product Development Milestones 65

Featured News & Press Releases 65

Nov 01, 2010: Synta Announces Gynecologic Oncology Group To Initiate Phase II Clinical Trial Of Elesclomol For Treatment Of Ovarian Cancer 65

Oct 22, 2010: M's Science Corporation Sells Its HF10 Oncology Business To Takara Bio Inc. 65

Sep 17, 2010: M's Science Corporation Initiates Exclusive Negotiations With Takara Bio Inc. To Sell Its HF10 Oncology Business 66

Sep 02, 2010: Oncolytics Biotech Announces Phase II Ovarian Cancer Study To Be Conducted By Gynecologic Oncology Group 66

Oct 16, 2009: National Patent Granted For Developmental Product HF 10 67

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 69

Disclaimer 69



List of Tables

Number of Products Under Development for Peritoneal Tumor, H2 2013 8

Products under Development for Peritoneal Tumor - Comparative Analysis, H2 2013 9

Number of Products under Development by Companies, H2 2013 11

Number of Products under Investigation by Universities/Institutes, H2 2013 12

Comparative Analysis by Late Stage Development, H2 2013 13

Comparative Analysis by Mid Clinical Stage Development, H2 2013 14

Comparative Analysis by Early Clinical Stage Development, H2 2013 15

Products under Development by Companies, H2 2013 16

Products under Investigation by Universities/Institutes, H2 2013 17

Boehringer Ingelheim GmbH, H2 2013 18

Amgen Inc., H2 2013 19

Eli Lilly and Company, H2 2013 20

Daiichi Sankyo Company, Ltd, H2 2013 21

Cell Therapeutics, Inc., H2 2013 22

Marshall Edwards, Inc., H2 2013 23

CritiTech, Inc., H2 2013 24

RECEPTA Biopharma S.A., H2 2013 25

Assessment by Monotherapy Products, H2 2013 26

Assessment by Stage and Route of Administration, H2 2013 28

Assessment by Stage and Molecule Type, H2 2013 30

Peritoneal Tumor Therapeutics - Drug Profile Updates 57

Peritoneal Tumor Therapeutics - Discontinued Products 63

Peritoneal Tumor Therapeutics - Dormant Products 64



List of Figures

Number of Products under Development for Peritoneal Tumor, H2 2013 8

Products under Development for Peritoneal Tumor - Comparative Analysis, H2 2013 9

Products under Development by Companies, H2 2013 10

Products under Investigation by Universities/Institutes, H2 2013 12

Late Stage Products, H2 2013 13

Mid Clinical Stage Products, H2 2013 14

Early Clinical Stage Products, H2 2013 15

Assessment by Monotherapy Products, H2 2013 26

Assessment by Route of Administration, H2 2013 27

Assessment by Stage and Route of Administration, H2 2013 28

Assessment by Molecule Type, H2 2013 29

Assessment by Stage and Molecule Type, H2 2013 30